{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:15:00Z","timestamp":1786540500297,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.urolonc.2026.111007","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T19:28:47Z","timestamp":1771010927000},"page":"111007","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Optimizing oncological outcomes in high-grade non-muscle invasive bladder cancer: The impact of a surgeon-led treatment pathway"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6126-9889","authenticated-orcid":false,"given":"Pietro","family":"Scilipoti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Rosiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Santangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Viti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Longoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Occhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Brancaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Tremolada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Folcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Zaurito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"de Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Mottrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Lucian\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Colecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Salonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.urolonc.2026.111007_bib0001","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-a summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111007_bib0002","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","article-title":"International Bladder Cancer Group consensus statement on clinical trial design for patients with Bacillus Calmette-Gu\u00e9rin-exposed high-risk non-muscle-invasive Bladder Cancer","volume":"82","author":"Roumigui\u00e9","year":"2022","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111007_bib0003","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.111007_bib0004","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000049765","article-title":"Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU group phase II protocol 30861","volume":"40","author":"Jakse","year":"2001","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111007_bib0005","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1097\/JU.0000000000001633","article-title":"Contemporary outcomes of patients with nonmuscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: implications for clinical trial design","volume":"205","author":"Matulay","year":"2021","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111007_bib0006","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.euo.2023.07.012","article-title":"Oncological outcomes for patients with European Association of Urology very high-risk non-muscle-invasive bladder cancer treated with Bacillus Calmette-Gu\u00e9rin or early radical cystectomy","volume":"6","author":"Contieri","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111007_bib0007","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.euo.2024.01.017","article-title":"Unlocking the potential of adequate Bacillus Calmette-Gu\u00e9rin immunotherapy in very-high-risk non-muscle-invasive bladder carcinoma: a multicenter analysis of oncological outcomes and risk dynamics","volume":"7","author":"Subiela","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111007_bib0008","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.21037\/tau.2019.09.38","article-title":"Transurethral resection of bladder tumour (TURBT)","volume":"9","author":"Kim","year":"2020","journal-title":"Transl Androl Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111007_bib0009","first-page":"6459","article-title":"The presence of detrusor muscle in the pathological specimen after transurethral resection of primary pT1 bladder tumors and its relationship to operator experience","volume":"19","author":"Roupr\u00eat","year":"2012","journal-title":"Can J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111007_bib0010","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3109\/21681805.2016.1163616","article-title":"Impact of resident involvement in endoscopic bladder cancer surgery on pathological outcomes","volume":"50","author":"Bos","year":"2016","journal-title":"Scand J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111007_bib0011","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4103\/UA.UA_138_19","article-title":"Role of surgeon experience in the outcome of transurethral resection of bladder tumors","volume":"12","author":"Ali","year":"2020","journal-title":"Urol Ann"},{"key":"10.1016\/j.urolonc.2026.111007_bib0012","unstructured":"Sylvester R.J., Rodr\u00edguez O., Hern\u00e1ndez V., et al. European Association of Urology (EAU) Prognostic Factor Risk Groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 Classification Systems for grade: an update from the EAU NMIBC Guidelines Panel [published correction appears in Eur Urol]. 2023;83(5):e140-e141. doi: 10.1016\/j.eururo.2023.02.007. Eur Urol. 2021;79(4):480-488. 10.1016\/j.eururo.2020.12.033"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111007_bib0013","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.euf.2024.06.007","article-title":"The impact of second opinion expert pathology review in patient management at the time of transurethral resection of the bladder","volume":"10","author":"Robesti","year":"2024","journal-title":"Eur Urol Focus"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111007_bib0014","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111007_bib0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","article-title":"International Bladder Cancer Group consensus statement on clinical trial design for patients with Bacillus Calmette-Gu\u00e9rin-exposed high-risk non-muscle-invasive Bladder Cancer","volume":"82","author":"Roumigui\u00e9","year":"2022","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.111007_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102241","article-title":"Risk of metachronous upper tract urothelial carcinoma after ureteral stenting in patients with bladder cancer","volume":"22","author":"Scilipoti","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"23","key":"10.1016\/j.urolonc.2026.111007_bib0017","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/jama.2020.7819","article-title":"Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial","volume":"323","author":"Thomas","year":"2020","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.urolonc.2026.111007_bib0018","doi-asserted-by":"crossref","first-page":"333.e1","DOI":"10.1016\/j.urolonc.2024.11.002","article-title":"Exploring the effect of patient characteristics on the association between warm ischemia time and the risk of postoperative acute kidney injury after partial nephrectomy","volume":"43","author":"Scilipoti","year":"2025","journal-title":"Urol Oncol."},{"issue":"5","key":"10.1016\/j.urolonc.2026.111007_bib0019","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/JU.0000000000002855","article-title":"Not all adverse pathology features are equal: identifying optimal candidates for adjuvant radiotherapy among patients with adverse pathology at radical prostatectomy","volume":"208","author":"Mazzone","year":"2022","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.urolonc.2026.111007_bib0020","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.urolonc.2020.06.013","article-title":"Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: a systematic review","volume":"38","author":"Mori","year":"2020","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111007_bib0021","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.euf.2017.09.002","article-title":"Discrepancy between European Association of Urology Guidelines and Daily practice in the management of non-muscle-invasive bladder cancer: results of a European survey","volume":"5","author":"Hendricksen","year":"2019","journal-title":"Eur Urol Focus"},{"issue":"10","key":"10.1016\/j.urolonc.2026.111007_bib0022","doi-asserted-by":"crossref","first-page":"796.e1","DOI":"10.1016\/j.urolonc.2020.04.026","article-title":"Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members","volume":"38","author":"Matulay","year":"2020","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111007_bib0023","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.euf.2023.07.002","article-title":"Repeat transurethral resection for non-muscle-invasive bladder cancer: an updated systematic review and meta-analysis in the contemporary era","volume":"10","author":"Yanagisawa","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2026.111007_bib0024","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.eururo.2024.09.013","article-title":"The role of multiparametric Magnetic resonance imaging and the Vesical imaging-reporting and Data system (VI-RADS) in the management of patients with bladder cancer: vision of the American College of Radiology VI-RADS Steering Committee","volume":"86","author":"Montorsi","year":"2024","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.111007_bib0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.3800","article-title":"Estimated costs and long-term outcomes of patients with high-risk non-muscle-invasive bladder cancer treated with Bacillus Calmette-Gu\u00e9rin in the Veterans Affairs Health System","volume":"4","author":"Williams","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111007_bib0026","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance Bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111007_bib0027","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2014.06.040","article-title":"Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Gu\u00e9rin: results of a retrospective multicenter study of 2451 patients","volume":"67","author":"Gontero","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.111007_bib0028","article-title":"Efficacy and safety of checkpoint inhibitors combined with Bacillus Calmette-Gu\u00e9rin (BCG) in BCG-na\u00efve high-risk non-muscle-invasive bladder cancer: synthesis of evidence from the ALBAN, CREST, and POTOMAC trials","author":"Scilipoti","year":"2025","journal-title":"Eur Urol."},{"issue":"6","key":"10.1016\/j.urolonc.2026.111007_bib0029","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bju.16645","article-title":"Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results","volume":"135","author":"Scilipoti","year":"2025","journal-title":"BJU Int."},{"issue":"5","key":"10.1016\/j.urolonc.2026.111007_bib0030","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2024.12.002","article-title":"The financial burden of localized and metastatic bladder cancer","volume":"87","author":"Scilipoti","year":"2025","journal-title":"Eur Urol."},{"issue":"3","key":"10.1016\/j.urolonc.2026.111007_bib0031","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.eururo.2025.05.005","article-title":"Management dilemma for very high-risk non-muscle-invasive bladder cancer: real-world data challenge the guideline recommendation for upfront radical cystectomy","volume":"88","author":"Subiela","year":"2025","journal-title":"Eur Urol"},{"issue":"6 Pt 1","key":"10.1016\/j.urolonc.2026.111007_bib0032","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1016\/j.juro.2006.08.004","article-title":"Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium","volume":"176","author":"Shariat","year":"2006","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.111007_bib0033","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bju.16675","article-title":"Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer","volume":"136","author":"Scilipoti","year":"2025","journal-title":"BJU Int."},{"key":"10.1016\/j.urolonc.2026.111007_bib0034","first-page":"157","article-title":"Managing the adverse events of intravesical bacillus Calmette-Gu\u00e9rin therapy","volume":"7","author":"Decaestecker","year":"2015","journal-title":"Res Rep Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.111007_bib0035","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.euf.2023.11.007","article-title":"Quinolone prophylaxis in conjunction with Bacillus Calmette-Gu\u00e9rin instillations for bladder cancer: time to reconsider the evidence and open the Quinolone box?","volume":"10","author":"Liedberg","year":"2024","journal-title":"Eur Urol Focus"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926000189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926000189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:51:16Z","timestamp":1784548276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926000189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1078143926000189"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111007","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing oncological outcomes in high-grade non-muscle invasive bladder cancer: The impact of a surgeon-led treatment pathway","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.111007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111007"}}